Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $31.1 million.

  • Taysha Gene Therapies' Non-cash Items rose 9217.9% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year increase of 9217.9%. This contributed to the annual value of $15.5 million for FY2024, which is 69081.63% up from last year.
  • Taysha Gene Therapies' Non-cash Items amounted to $31.1 million in Q3 2025, which was up 9217.9% from $22.2 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Non-cash Items peaked at $47.4 million during Q1 2022, and registered a low of $62000.0 during Q4 2022.
  • Moreover, its 4-year median value for Non-cash Items was $16.9 million (2024), whereas its average is $19.3 million.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Non-cash Items showed a top increase of 306129.03% in 2023 and a maximum decrease of 7341.77% in 2023.
  • Taysha Gene Therapies' Non-cash Items (Quarter) stood at $62000.0 in 2022, then surged by 3061.29% to $2.0 million in 2023, then skyrocketed by 690.82% to $15.5 million in 2024, then surged by 100.86% to $31.1 million in 2025.
  • Its Non-cash Items stands at $31.1 million for Q3 2025, versus $22.2 million for Q2 2025 and $22.2 million for Q1 2025.